Skip to main content

Table 3 Complete case analysis

From: Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations in Uganda

Characteristic Unadjusted OR (95% CI) p-value Adjusted OR (95% CI) p-value
Gender
Female 1.00   1.00  
Male 3.09(1.80–5.31)  < 0.001 2.58(1.42–4.69) 0.002*
Type of second-line drugs
lopinavir 1.00   1.00  
Atazanavir 1.59(0.44–5.82) 0.483 3.4(0.79–14.34) 0.101
Other PIµ 5.66(1.92–16.66) 0.002 3.92(1.15–13.38) 0.671
TB treatment
No 1.00   1.00  
Yes 7.54(2.69–21.08)  < 0.001 5.65(1.76–18.09) 0.004*
Year of ART initiation
Before 2001 1.00   1.00  
2001–2005 0.05(0.01–0.16)  < 0.001 0.06(0.02–0.22)  < 0.001*
2006–2010 0.05(0.02–0.20)  < 0.001 0.07(0.02–0.28)  < 0.001*
2011–2015 0.02(0.00–0.17)  < 0.001 0.03(0.00–0.26) 0.002*
Type of 1st line drug
NNRTI based 1.00    
NON-NNRTI 1.81(0.92–3.55) 0.085
Other comorbidities
No 1.00    
Yes 1.00(0.44–2.26) 1.000
Age at start of 2nd line
  0.99(0.97–1.01) 0.300
CD4 at start of second line
  0.99(0.99–1.00) 0.079
Duration on 1st line
  1.07(0.96–1.18) 0.210   
  1. Wide confidence interval due to small sample size *statistically significant at the 5% level, TB: tuberculosis, VL: Viral Load, IQR: Interquartile Range, ART: Antiretroviral Therapy, ∞Non-NRTI: triple nucleosides, µ “other PI”: saquinavir and nelfinavir